All In Biotech

Drug Trial Radar · NCT07861100

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 8,500 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

8,500

Planned (sponsor's estimate)

Start

Oct 26, 2026

Primary completion

Sep 16, 2030

Study completion Sep 16, 2030

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Oct 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have ASCVD and excess body weight. Participants will be randomly assigned by chance to receive either zenagamtide, the investigational treatment being tested, or a placebo, which contains no active medicine. Half of the participants will receive zenagamtide, and treatment assignment will be determined randomly. Zenagamtide is a new investigational medicine that is not yet available for prescription by doctors.

Conditions

  • Cardiovascular Risk
  • Obesity

Interventions

  • ZenagamtideDrug

    Zenagamtide will be administered subcutaneously.

  • PlaceboDrug

    Placebo will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from randomization to first occurrence of a 4-point (P) composite major adverse cardiovascular events (MACE) endpoint consisting of: Cardiovascular (CV) death, Non-fatal MI, Non-fatal stroke, HF hospitalization or urgent HF visitTime frame: From baseline (week 0) to up to 203 weeks or longer

Locations

769 sites in 26 countries. Site status is shown where the registry gives one.

  • Uni of Alabama at Birmingham

    Birmingham, Alabama

  • Eastern Shore Rsrch Inst, LLC

    Fairhope, Alabama

  • Mobile Heart Specialists

    Mobile, Alabama

  • Chambliss Clinical Trials LLC

    Montgomery, Alabama

  • Mercy Gilbert Medical Center

    Gilbert, Arizona

  • Sun City Clinical Research

    Glendale, Arizona

  • Honor Health

    Scottsdale, Arizona

  • Clinical Research Institute of Arizona

    Surprise, Arizona

  • National Heart Institute Cal

    Beverly Hills, California

  • California Inst Of Renal Res

    Chula Vista, California

  • Valley Clinical Trials

    Covina, California

  • First Valley Medical Group

    Lancaster, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • Pacific Clinical Studies

    Los Alamitos, California

  • Academic Medical Research Institute

    Los Angeles, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • Clinical Trials Research_Sacramento

    Sacramento, California

  • Paradigm Clinical Research

    San Diego, California

  • N America Res Inst - San Dimas

    San Dimas, California

  • Fomat Medical Research

    Santa Maria, California

  • Bridgeport Hospital

    Bridgeport, Connecticut

  • Innovative Research of W FL

    Clearwater, Florida

  • Nature Coast Clin Rsrch_Crystal River

    Crystal River, Florida

  • Florida Premier Cardiology

    Delray Beach, Florida

  • Encore Medical Research LLC

    Hollywood, Florida

  • Est Cst Inst for Rsrch,Jksnvil

    Jacksonville, Florida

  • Jacksonville Ctr Clin Res

    Jacksonville, Florida

  • Clinical Research of Cent FL

    Lakeland, Florida

  • K2 Medical Research

    Maitland, Florida

  • Life Spring Research Foundation LLC

    Miami, Florida

  • Flourish Research - North Miami

    Miami, Florida

  • Oceane 7 Medical & Research Center, Inc.

    Miami, Florida

  • San Marcus Res Clin Miami Lakes

    Miami Lakes, Florida

  • Advance Rsch for Hlth Improvement_Naples

    Naples, Florida

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida

  • Ocala Cardiovascular Research

    Ocala, Florida

  • Oviedo Medical Research, LLC

    Oviedo, Florida

  • Cardio Partners Clin Res Inst

    Palm Beach Gardens, Florida

  • Suncoast Clinical Research, Inc.

    Palm Harbor, Florida

Showing 40 of 769 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.